L
Título: GRANISETRON COMPARED WITH ONDANSETRON PLUS DEXAMETHASONE IN THE PREVENTION OF NAUSEA AND VOMITING INDUCED BY A INTENSELY EMETOGENIC CHEMOTHERAPY REGIMEN: A RANDOMIZED CROSS-OVER STUDY
Autores: Yu, Ding
Deng, Huabang
Fan, Yuhua
Fu, Xiaoyu
Ke, Yuhua
Hu, Yanping
Zhou, Yunhua
Yang, Ling
Fecha: 2013-07-24
Publicador: Chinese Journal of Cancer Research
Fuente: Ver documento
Tipo:
Tema: No aplica
Descripción: Fifty-two patients with chemotherapy comprise cisplatin, adriamycin and dacarbazine underwent antiemetic therapy form September 1994 to June 1995. The chemotherapy regimens include CAP-VDS, ACO, EP, CHOP, AMF and MFP. The dose of PDD was 60-70 mg/M2,ADR was 40-50 mg/M2 and DTIC was 300 mg/M2. This study was the randomized, cross-over study, ruled out any differences between individual patients. Group A: Granisetron was given on the first day of chemotherapy, Granisetron 3 mg, Dexamethasone l0 mg i.v. at 30 minutes before chemotherapy; Group B: Ondansetron was given on the first and second days, Ondansetron 8 rag, Dexamethasone 10 mg i.v. at 30 minutes before chemo-therapy. The rates of complete control-free of vomiting were 80.8% and 82.7% in both groups respectively at 24 hours (P>0.05), 57.7% and 53.9% respectively (P>0.05)at second day, and 67.3% and 53.9% respectively (P<0.05) at third day. No difference was observed between both groups for the result of antiemetic control in seven days, the rate of overall control are 82.7% and 80.8% respectively (P>0.05). Adverse eventswith both antiemetic treatments were mild (essentially headache), the percentage of headache with ondansetron was 9.5% and granisetron 7.7%, constipation with ondansetron was 80.8% and granisetron 61.5%. Constipation: Granisetron, given as one i.v. 3 mg injection before chemotherapy plus dexamethasone, and ondansetron, given intravenously 8 mg injection before chemotherapy at the first 2 days plus dexamethasone are similar results on acute and dalayed chemotherapy induced vomiting in patients receiving their intensely emetogenic regimen.
Idioma: Inglés
Artículos similares:
A Phase II Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China por Yang, Lu,Wang, Zhi-jie,An, Tong-tong,Bai, Hua,Zhao, Jun,Duan, Jian-chun,Li, Ping-ping,Wu, Mei-na,Sun, Hong,Liang, Li,Wang, Jie
Risk Factors And Outcome of Pancreatic Fistula after Consecutive Pancreaticoduodenectomy with Pancreaticojejunostomy for Patients with Malignant Tumor por Zhu, Wei-hua,Li, Shu,Zhang, Da-fang,Peng, Ji-run,Jin, Zhong-tian,Li, Guang-ming,Wang, Fu-shun,Zhu, Ji-ye,Leng, Xi-sheng
Polymorphisms of XPC Gene And Susceptibility of Esophageal Cancer por Feng, Xiang-xian,Duan, Pei-fen,Wang, Li-bing,Lu, Zu-xun
Location of Sentinel Lymph Node in Gastric Cancer: A Modified, Painless And Noninvasive Approach por Su, Xin-hui,Chen, Qiang,Sun, Long,Wu, Hua,Pan, Wei-Ming,Chen, Gui-bing,Luo, Zuo-Ming,Wang, Wei
Low Correspondence of EGFR Mutations in Tumor Tissue And Paired Serum of Non-Small-Cell Lung Cancer Patients por Song, Guo-hong,Ren, Jun,Zhang, Li-jian,Di, Li-jun,Yuan, Yan-hua,Yu, Jing,Jia, Jun
10 
Combined Antitumor Effect of Ursolic Acid And 5-Fluorouracil on Human Esophageal Carcinoma Cell Eca-109 In Vitro por Chen, Guo-qing,Yao, Zhen-wei,Zheng, Wei-ping,Chen, Li,Duan, Hong,Shen, Yi